The MFSD2A (Major Facilitator Superfamily Domain Containing 2A) antibody is a critical tool for studying the function and expression of the MFSD2A protein, a transmembrane transporter belonging to the major facilitator superfamily. MFSD2A is primarily expressed in the endothelium of the blood-brain barrier (BBB) and plays a vital role in transporting essential lipids, such as docosahexaenoic acid (DHA), into the brain. It is also implicated in maintaining BBB integrity by regulating vesicular transcytosis. Dysregulation of MFSD2A has been linked to neurological disorders, including cognitive deficits and neurodevelopmental impairments.
The antibody enables researchers to detect MFSD2A in various experimental settings, such as Western blotting, immunohistochemistry, and flow cytometry, aiding in the investigation of its tissue distribution, expression levels, and interactions. Studies using MFSD2A antibodies have revealed its reduced expression in aging brains and certain disease models, such as Alzheimer’s disease and stroke. Additionally, genetic knockout models validated by antibody-based assays highlight MFSD2A’s role in lipid homeostasis and neuroprotection.
Understanding MFSD2A’s mechanisms through antibody-mediated research holds promise for developing therapies targeting BBB dysfunction or lipid metabolism disorders. Its specificity and reliability make it indispensable for both basic and translational neuroscience studies.